MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...
MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...
After starting my career at PCMag as an intern more than a decade ago, I’m back as one of its editors, focused on managing laptops, desktops, and components coverage. With 15 years of experience, I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback